000088480 001__ 88480
000088480 005__ 20210902121634.0
000088480 0247_ $$2doi$$a10.3390/ijms21051881
000088480 0248_ $$2sideral$$a117242
000088480 037__ $$aART-2020-117242
000088480 041__ $$aeng
000088480 100__ $$0(orcid)0000-0003-0195-5434$$aSalillas, Sandra$$uUniversidad de Zaragoza
000088480 245__ $$aFlavodoxins as novel therapeutic targets against helicobacter pylori and other gastric pathogens
000088480 260__ $$c2020
000088480 5060_ $$aAccess copy available to the general public$$fUnrestricted
000088480 5203_ $$aFlavodoxins are small soluble electron transfer proteins widely present in bacteria and absent in vertebrates. Flavodoxins participate in different metabolic pathways and, in some bacteria, they have been shown to be essential proteins representing promising therapeutic targets to fight bacterial infections. Using purified flavodoxin and chemical libraries, leads can be identified that block flavodoxin function and act as bactericidal molecules, as it has been demonstrated for Helicobacter pylori (Hp), the most prevalent human gastric pathogen. Increasing antimicrobial resistance by this bacterium has led current therapies to lose effectiveness, so alternative treatments are urgently required. Here, we summarize, with a focus on flavodoxin, opportunities for pharmacological intervention offered by the potential protein targets described for this bacterium and provide information on other gastrointestinal pathogens and also on bacteria from the gut microbiota that contain flavodoxin. The process of discovery and development of novel antimicrobials specific for Hp flavodoxin that is being carried out in our group is explained, as it can be extrapolated to the discovery of inhibitors specific for other gastric pathogens. The high specificity for Hp of the antimicrobials developed may be of help to reduce damage to the gut microbiota and to slow down the development of resistant Hp mutants.
000088480 536__ $$9info:eu-repo/grantAgreement/ES/DGA/LMP30-18$$9info:eu-repo/grantAgreement/ES/MINECO/BFU2016-78232-P
000088480 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000088480 590__ $$a5.923$$b2020
000088480 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b67 / 297 = 0.226$$c2020$$dQ1$$eT1
000088480 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b49 / 178 = 0.275$$c2020$$dQ2$$eT1
000088480 592__ $$a1.455$$b2020
000088480 593__ $$aCatalysis$$c2020$$dQ1
000088480 593__ $$aComputer Science Applications$$c2020$$dQ1
000088480 593__ $$aInorganic Chemistry$$c2020$$dQ1
000088480 593__ $$aSpectroscopy$$c2020$$dQ1
000088480 593__ $$aMolecular Biology$$c2020$$dQ1
000088480 593__ $$aOrganic Chemistry$$c2020$$dQ1
000088480 593__ $$aPhysical and Theoretical Chemistry$$c2020$$dQ1
000088480 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000088480 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000088480 700__ $$0(orcid)0000-0002-2879-9200$$aSancho, Javier$$uUniversidad de Zaragoza
000088480 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000088480 773__ $$g21, 5 (2020), 1881 [26 pp.]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000088480 8564_ $$s1682746$$uhttps://zaguan.unizar.es/record/88480/files/texto_completo.pdf$$yVersión publicada
000088480 8564_ $$s489482$$uhttps://zaguan.unizar.es/record/88480/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000088480 909CO $$ooai:zaguan.unizar.es:88480$$particulos$$pdriver
000088480 951__ $$a2021-09-02-08:54:56
000088480 980__ $$aARTICLE